Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotac PharmaceuticalsNSE:SOTAC 58 PE Ratio (TTM) is 18.22 as of Jul. 21, 2026, which is 38% below its 10-year median of 29.49. GuruFocus rates NSE:SOTAC with a GF Score™ of 58/100 and a GF Value™ of ₹141.03 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 639 Drug Manufacturers companies, Sotac Pharmaceuticals ranks better than 57.12% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-21), Sotac Pharmaceuticals's share price is
₹95.10.
Sotac Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5.22. Therefore, Sotac Pharmaceuticals's PE Ratio (TTM) for today is 18.22.
The historical rank and industry rank for Sotac Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:
NSE:SOTAC'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 13.77 Med: 29.49 Max: 59.48
Current: 18.22
During the past 7 years, the highest PE Ratio (TTM) of Sotac Pharmaceuticals was 59.48. The lowest was 13.77. And the median was 29.49.
NSE:SOTAC's PE Ratio (TTM) is ranked better than 57.12% of 639
companies
in the Drug Manufacturers industry
Industry Median: 21.04
vs NSE:SOTAC: 18.22
During the past 7 years, Sotac Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 204.80% per year. The lowest was 32.60% per year. And the median was 40.70% per year.
Sotac Pharmaceuticals (NSE:SOTAC) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Sotac Pharmaceuticals PE Ratio (TTM) Related Terms
Sotac Pharmaceuticals PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Sotac Pharmaceuticals's Share Price of today is ₹95.10.
For company reported semi-annually, Sotac Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹5.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Sotac Pharmaceuticals (NSE:SOTAC) has a PE Ratio (TTM) of 18.22 as of Jul. 21, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Sotac Pharmaceuticals and its competitors. This is 38% below median its historical median of 29.49. Over the past decade, Sotac Pharmaceuticals' PE Ratio (TTM) has ranged from 13.77 to 59.48. According to the industry distribution chart, Sotac Pharmaceuticals ranks #274 out of 639 companies in the Drug Manufacturers industry, placing it in the top 42.9%.
Is Sotac Pharmaceuticals' PE Ratio (TTM) too high?
Sotac Pharmaceuticals' current PE Ratio (TTM) of 18.22 is 38% below median its 10-year median of 29.49. Over the past 10 years, this metric has ranged from a low of 13.77 to a high of 59.48. The Drug Manufacturers industry median PE Ratio (TTM) is 21.04. Sotac Pharmaceuticals' value of 18.22 is 13.4% below this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #274 out of 639 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sotac Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' PE Ratio (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #274 out of 639 companies for PE Ratio (TTM). This puts Sotac Pharmaceuticals in the upper half of its industry. The industry median PE Ratio (TTM) is 21.04. Sotac Pharmaceuticals' value of 18.22 is 13.4% below this benchmark. Historically, Sotac Pharmaceuticals' own PE Ratio (TTM) has ranged from 13.77 to 59.48 over the past decade. While the company's 10-year median is 29.49 vs. the industry median of 21.04, Sotac Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 21.04, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current PE Ratio (TTM) of 18.22 is 13.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 21.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current PE Ratio (TTM) is 18.22, which is 38% below median its own 10-year median of 29.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹141.03, compared to a current price of ₹95.10 — trading 32.6% below its estimated fair value. The current PE Ratio (TTM) is 18.22, which is 38% below median its 10-year median of 29.49 and 13.4% below the Drug Manufacturers industry median of 21.04. Sotac Pharmaceuticals' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current PE Ratio (TTM) is 18.22 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹95.10 is trading 32.6% below its estimated GF Value™ of ₹141.03.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
PE Ratio (TTM): 18.22 (38% below median its 10-year median of 29.49)
GF Value™: ₹141.03 vs. price of ₹95.10 (32.6% below fair value)
Industry Position: 13.4% below the Drug Manufacturers median (#274 of 639)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
58GF Score
Get the complete analysis for NSE:SOTAC
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
